Abstract: Melanoma is characterized by high mortality and poor prognosis. The novel immunotherapy has offered a breakthrough in antitumor activity in melanoma and has offered incremental improvements over standard care. The ASCO annual meeting held on June 1, 2018 in Chicago, was conducted to present the progress of current treatment and promise of those still in clinical development. The academic event showed results of clinical trials in patients with lymph node dissection, adjuvant therapy, immunotherapy, and targeted therapy. Melanoma drugs introduced at the meeting included NIVO, Pembro, T-VEC, Encorafenib, Binimetinib, and CDk4/6i. The development of therapy is retrospected in this paper in order to provide a basis and give hope for melanoma treantment in China.